May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Rabbit ocular mucosal immune system stimulated by HSV–1 gD peptides mixed with the mucosal adjuvant CpG and administered mucosally as eye drops
Author Affiliations & Notes
  • A.B. Nesburn
    Department of Ophthalmology, University California Irvine, Orange, CA
  • T.V. Ramos
    Department of Ophthalmology, University California Irvine, Orange, CA
  • X. Zhu
    Department of Ophthalmology, University California Irvine, Orange, CA
  • S.L. Wechsler
    Department of Ophthalmology, University California Irvine, Orange, CA
  • L. BenMohamed
    Department of Ophthalmology, University California Irvine, Orange, CA
  • Footnotes
    Commercial Relationships  A.B. Nesburn, None; T.V. Ramos, None; X. Zhu, None; S.L. Wechsler, None; L. BenMohamed, None.
  • Footnotes
    Support  EY09392 & EY14900
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1661. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.B. Nesburn, T.V. Ramos, X. Zhu, S.L. Wechsler, L. BenMohamed; Rabbit ocular mucosal immune system stimulated by HSV–1 gD peptides mixed with the mucosal adjuvant CpG and administered mucosally as eye drops . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1661.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:Mucosal surfaces constitute an impressive first–line defense system that is frequently exposed to an array of exogenous antigens and pathogens. The Ocular Mucosal Immune System or OMIS, is the immune barrier that protects the surface of the eye. OMIS plays a crucial role in ocular immunity, tolerance and inflammation. Understanding and being able to manipulate OMISimmunity is the first step in developing protection against serious external–ocular infections, such as HSV. Methods: We conducted ocular immunizations using several well–characterized immunogenic peptides derived from herpes simplex virus type 1 (HSV–1) glycoprotein–D, together with CpG mucosal adjuvant in rabbits. All rabbits received two eye drops in both eyes (given at 21 day intervals for 3 doses) of a pool of peptides (100microg each peptide) + CpG 2007 mucosal adjuvant (100microg of CpG per dose) in a total volume of 25microL. Control animals received the CpG 2007 alone. The CpG 2007 adjuvant was chosen because it was previously shown to enhance B and T cell immunogenicity in rabbits (Coley Pharmaceutical Group). Animals were studied for 3 mos for ocular mucosal and systemic B and T cell responses. Results: Ocular administration of HSV–1 gD peptides containing predicted B and T cell epitopes emulsified with CpG DNA induced both systemic and ocular mucosal immune responses in rabbits. Both IgA and IgG antibody responses were obtained against each of the individual peptides composing the pool. Peptide and HSV–1 specific sIgA was elicited in tears. Peptide specific T cells were induced in the conjunctiva and in PBMCs . Conclusions: These data prove that topical administration of HSV–1 peptide epitopes and CpG adjuvant stimulated (a) HSV specific local antibody response (tear IgA & IgG), (b) a local ocular T cell response (predominantly Th–1), and (c) systemic cellular immune responses.

Keywords: herpes simplex virus • immunomodulation/immunoregulation • antigen presentation/processing 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×